Skip to main content

Coherus Oncology, Inc.

corporate_fare Company Profile

Coherus Oncology, Inc.

CHRS·NASDAQ·Life Sciences·CIK 0001512762

Coherus Oncology, Inc. is a commercial-stage oncology company focused on innovative cancer treatments. The company's primary product is LOQTORZI® (toripalimab-tpzi), an approved next-generation programmed death receptor-1 ("PD-1") inhibitor. LOQTORZI was approved by the U.S. Food and Drug Administration ("FDA") on October 27, 2023, for the first-line treatment of adults with metastatic or recurrent locally advanced nasopharyngeal carcinoma ("NPC") in combination with cisplatin and gemcitabine. It is also approved as a monotherapy for adults with recurrent unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. LOQTORZI, an anti-PD-1 antibody, was developed in collaboration with Junshi Biosciences Co., Ltd. and launched in the U.S. on January 2, 2024. It is currently the only FDA-approved immune checkpoint inhibitor for these NPC indications commercially available in the United States. The company's strategy involves growing LOQTORZI sales in NPC and developing new indications for LOQTORZI in combination with its pipeline candidates and partners. Coherus Oncology, Inc. changed its corporate name from "Coherus BioSciences, Inc." on May 29, 2025, to reflect its exclusive focus on proprietary immuno-oncology medicines following the divestitures of its biosimilar businesses. The pipeline includes two mid-stage clinical candidates targeting liver, head and neck, colorectal, and other cancers, which are planned for development in combination with LOQTORZI and other immune activating or cancer agents. One such candidate is casdozokitug (CHS-388, formerly SRF388), an investigational antagonist antibody targeting IL-27, which received orphan drug designation from the FDA for hepatocellular carcinoma ("HCC") in October 2020.

Coherus Oncology, Inc. (NASDAQ:CHRS) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 29 items for CHRS at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Coherus Oncology Completes Strategic Pivot, Reduces Debt, and Secures $47M in New Capital
  • Coherus Oncology Reports Q4 Sales Miss, Significant Debt Reduction, and Strong Cash Position
  • Coherus Oncology Q4 Sales Miss Estimates by $1.15M, Adjusted Net Income Also Falls Short
  • Coherus Oncology Completes $47 Million Public Offering
  • Coherus Oncology Finalizes $50.05M Public Offering, Securing Operating Capital

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$42.17M
Net Income
$168.02M
Diluted EPS
$1.43
Op. Cash Flow
-$138.51M
Gross Profit
$28.36M
Operating Income
-$181.13M
Cash & Equivalents
$88.88M
Debt / Equity
0.00×
Net Margin
398.4%
Shares Outstanding
121.15M sh
Source: 10-K · filed 2026-03-09 · accession 0001104659-26-025308
$0.3799 +2.73% today
52-week range · as of 2026-11-09 $0.3799 – $2.62
Market cap
$57.15M
Volume
2.5M (1.1× avg)
3-mo avg 2.3M
Live data · 2026-11-22 12:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed CHRS - Filings & News (Page 2)

CHRS
Mar 09, 2026, 4:56 PM EDT
Filing Type: 10-K
Importance Score:
9
Price at Filing: $1.90
Real-time Price: $0.3799 info
Change: -$1.52 (-80%) info
Market Cap: $57.148M info
CHRS
Mar 09, 2026, 4:40 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $1.84
Real-time Price: $0.3799 info
Change: -$1.46 (-79%) info
Market Cap: $57.148M info
CHRS
Mar 09, 2026, 4:15 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $1.80
Real-time Price: $0.3799 info
Change: -$1.42 (-79%) info
Market Cap: $57.148M info
CHRS
Feb 17, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.61
Real-time Price: $0.3799 info
Change: -$1.23 (-76%) info
Market Cap: $57.148M info
CHRS
Feb 13, 2026, 5:10 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.63
Real-time Price: $0.3799 info
Change: -$1.25 (-77%) info
Market Cap: $57.148M info
CHRS
Feb 12, 2026, 4:08 PM EST
Filing Type: 424B5
Importance Score:
7
Price at Filing: $1.81
Real-time Price: $0.3799 info
Change: -$1.43 (-79%) info
Market Cap: $57.148M info
CHRS
Feb 04, 2026, 8:40 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $2.18
Real-time Price: $0.3799 info
Change: -$1.80 (-83%) info
Market Cap: $57.148M info
CHRS
Jan 23, 2026, 5:26 PM EST
Filing Type: 424B5
Importance Score:
8
Price at Filing: $1.97
Real-time Price: $0.3799 info
Change: -$1.59 (-81%) info
Market Cap: $57.148M info
CHRS
Jan 13, 2026, 9:00 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $1.74
Real-time Price: $0.3799 info
Change: -$1.36 (-78%) info
Market Cap: $57.148M info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets